Predictive value ofKRASmutations in chemoresistant CRC

    loading  Checking for direct PDF access through Ovid

Abstract

On the basis of the results ofKRASanalysis from the CO.17 randomized, controlled, phase III study by Karapetiset al., KRASmutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

Related Topics

    loading  Loading Related Articles